Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples